Japan uptake of Simponi music to Mitsubishi Tanabe's ears
This article was originally published in Scrip
Executive Summary
Simponi (golimumab) is so far living up to Mitsubishi Tanabe Pharma's (MTP) expectations in Japan, with sales of the monoclonal antibody for rheumatoid arthritis coming in slightly ahead of the firm's internal forecasts.